Advances in Fecal Occult Blood Tests: The FIT Revolution

被引:0
|
作者
Graeme P. Young
Erin L. Symonds
James E. Allison
Stephen R. Cole
Callum G. Fraser
Stephen P. Halloran
Ernst J. Kuipers
Helen E. Seaman
机构
[1] Flinders University,Flinders Centre for Innovation in Cancer L3:100
[2] Repatriation General Hospital,Bowel Health Service
[3] University of California,Division of Gastroenterology
[4] San Francisco (UCSF),Ninewells Hospital and Medical School, Centre for Research into Cancer Prevention and Screening
[5] San Francisco General Hospital,Department of Biochemistry and Physiology, School of Biosciences and Medicine
[6] Scottish Bowel Screening Research Unit,undefined
[7] University of Dundee,undefined
[8] NHS Bowel Cancer Screening Southern Programme Hub,undefined
[9] University of Surrey,undefined
[10] Erasmus MC University Medical Center Rotterdam,undefined
来源
Digestive Diseases and Sciences | 2015年 / 60卷
关键词
Colorectal cancer; Screening; Fecal occult blood test; FIT; Sensitivity; Specificity;
D O I
暂无
中图分类号
学科分类号
摘要
There is a wide choice of fecal occult blood tests (FOBTs) for colorectal cancer screening. Goal: To highlight the issues applicable when choosing a FOBT, in particular which FOBT is best suited to the range of screening scenarios. Four scenarios characterize the constraints and expectations of screening programs: (1) limited colonoscopy resource with a need to constrain test positivity rate; (2) a priority for maximum colorectal neoplasia detection with little need to constrain colonoscopy workload; (3) an “adequate” endoscopy resource that allows balancing the benefits of detection with the burden of service provision; and (4) a need to maximize participation in screening. Guaiac-based FOBTs (gFOBTs) have significant deficiencies, and fecal immunochemical tests (FITs) for hemoglobin have emerged as better tests. gFOBTs are not sensitive to small bleeds, specificity can be affected by diet or drugs, participant acceptance can be low, laboratory quality control opportunities are limited, and they have a fixed hemoglobin concentration cutoff determining positivity. FITs are analytically more specific, capable of quantitation and hence provide flexibility to adjust cutoff concentration for positivity and the balance between sensitivity and specificity. FITs are clinically more sensitive for cancers and advanced adenomas, and because they are easier to use, acceptance rates are high. Conclusions: FOBT must be chosen carefully to meet the needs of the applicable screening scenario. Quantitative FIT can be adjusted to suit Scenarios 1, 2 and 3, and for each, they are the test of choice. FITs are superior to gFOBT for Scenario 4 and gFOBT is only suitable for Scenario 1.
引用
收藏
页码:609 / 622
页数:13
相关论文
共 50 条
  • [1] Advances in Fecal Occult Blood Tests: The FIT Revolution
    Young, Graeme P.
    Symonds, Erin L.
    Allison, James E.
    Cole, Stephen R.
    Fraser, Callum G.
    Halloran, Stephen P.
    Kuipers, Ernst J.
    Seaman, Helen E.
    DIGESTIVE DISEASES AND SCIENCES, 2015, 60 (03) : 609 - 622
  • [2] Colorectal Cancer Screening by Fecal Immunochemical Tests (FIT): Considerations on Sampling and Markers (Hb and Hb/Hp Complex) of Fecal Occult Blood (FOB)
    Syrjaenen, Kari
    Eskelinen, Maaret
    Meklin, Jannica
    Hendolin, Panu
    Eskelinen, Matti
    Suovaniemi, Osmo
    ANTICANCER RESEARCH, 2024, 44 (04) : 1513 - 1523
  • [3] Colorectal Cancer Screening With Traditional and New-generation Fecal Immunochemical Tests: A Critical Review of Fecal Occult Blood Tests
    Meklin, Jannica
    Syrjanen, Kari
    Eskelinen, Matti
    ANTICANCER RESEARCH, 2020, 40 (02) : 575 - 581
  • [4] Use and abuse of fecal occult blood tests: a community hospital experience
    Sarthak Soin
    Olalekan Akanbi
    Abdullah Ahmed
    Yunha Kim
    Sarbagya Pandit
    Igor Wroblewski
    Nasir Saleem
    BMC Gastroenterology, 19
  • [5] Use and abuse of fecal occult blood tests: a community hospital experience
    Soin, Sarthak
    Akanbi, Olalekan
    Ahmed, Abdullah
    Kim, Yunha
    Pandit, Sarbagya
    Wroblewski, Igor
    Saleem, Nasir
    BMC GASTROENTEROLOGY, 2019, 19 (01)
  • [6] Challenges in the Management of Positive Fecal Occult Blood Tests
    Sandhya K. Rao
    Thad F. Schilling
    Thomas D. Sequist
    Journal of General Internal Medicine, 2009, 24
  • [7] Challenges in the Management of Positive Fecal Occult Blood Tests
    Rao, Sandhya K.
    Schilling, Thad F.
    Sequist, Thomas D.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2009, 24 (03) : 356 - 360
  • [8] Does acetylsalicylic acid or warfarin affect the accuracy of fecal occult blood tests?
    Gandhi, Sumeet
    Narula, Neeraj
    Gandhi, Samir
    Marshall, John K.
    Farkouh, Michael E.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 (06) : 931 - 936
  • [9] A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. a prospective, controlled, feasibility study
    Levi, Zohar
    Birkenfeld, Shlomo
    Vilkin, Alex
    Bar-Chana, Micha
    Lifshitz, Irena
    Chared, Miri
    Maoz, Eran
    Niv, Yaron
    INTERNATIONAL JOURNAL OF CANCER, 2011, 128 (10) : 2415 - 2424
  • [10] Fecal Occult Blood Tests in Colorectal Cancer Screening: Systematic Review and Meta-analysis of Traditional and New-generation Fecal Immunochemical Tests
    Meklin, Jannica
    Syrjanen, Kari
    Eskelinen, Matti
    ANTICANCER RESEARCH, 2020, 40 (07) : 3591 - 3604